Upstream Bio, INC 10-Q quarterly reports

Upstream Bio, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing ongoing clinical trial progress for its lead candidate, verekitug, while reporting continued net losses and a substantial accumulated deficit.

Upstream Bio, Inc. filed its Form 10-Q for the quarter ended March 31, 2026, detailing continued investment in its lead drug candidate, verekitug, and reporting a net loss.

Upstream Bio, a clinical-stage biopharmaceutical company, reported positive top-line results for verekitug in chronic rhinosinusitis with nasal polyps (CRSwNP) and advanced its severe asthma and COPD programs, while incurring increased net losses.

Upstream Bio reports significant progress in its verekitug clinical programs for severe asthma, CRSwNP, and COPD, with sufficient cash to fund operations through 2027.

Upstream Bio's Q1 2025 results show increased R&D spending as the company advances its verekitug clinical trials, with topline CRSwNP data expected in Q3 2025 and asthma data in H1 2026.

Upstream Bio, a clinical-stage biopharmaceutical company, released its third quarter 2024 financial results, highlighting ongoing clinical trials and financial activities.